Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2016 | short review | Ausgabe 2/2016 Open Access

memo - Magazine of European Medical Oncology 2/2016

CDK4/6 inhibition in luminal breast cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2016
Autoren:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Wichtige Hinweise
Authors’ contributions. All authors: data analysis and interpretation, final approval of manuscript; S. P. Gampenrieder: conception and design, collection and assembly of data, Manuscript writing; G. Rinnerthaler: manuscript writing, critical revising of the manuscript, critical revising of the manuscript; R. Greil: critical revising of the manuscript

Summary

Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4/6 inhibitor palbociclib has shown promising results in metastatic luminal breast cancer when used in combination with endocrine therapy both in the first-line setting as in pretreated women. The drug showed a manageable safety profile with uncomplicated neutropenia as the most frequent side effect. Approval was already granted in the US and is also awaited during 2016 for Europe.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe